Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
220 participants
OBSERVATIONAL
2023-03-31
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification of New Prognostic Markers for Breast Cancer.
NCT03436069
Prognostic Value of Biomarkers in HR + / HER2 - Advanced Breast Cancer
NCT04683770
PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale BREAST Cancers, PERCEIVE-BREAST
NCT06979921
Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Tumor Specimens in Breast Cancer
NCT01247480
Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment
NCT02326857
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard of care
Female patient diagnosed for breast cancer
Diagnostic assistance tool
Diagnostic assistance tool for analysis of 5 prognostic and predictive markers of breast cancer (HER2, Ki67 Index, Mitoses, Estrogen Hormone Receptor, Hormone Progesteron receptors hormone of Progesteronereceptor).
Each anatomo-histopathological slide will be re-read 3 times:
* Reading 1: first reading by a pathologist in the care setting
* Reading via the standard care procedure (microscope and physical slides)
* Reading 2: Second reading by another pathologist from the same center, as part of the research.
* Reading via the standard procedure of care (microscope and physical slides)
* Reading 3: Third reading by the initial physician, with the algorithmic tool MoSi4BCa after digitization of the slides by a laboratory technician and after a wash-out period of 2 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diagnostic assistance tool
Diagnostic assistance tool for analysis of 5 prognostic and predictive markers of breast cancer (HER2, Ki67 Index, Mitoses, Estrogen Hormone Receptor, Hormone Progesteron receptors hormone of Progesteronereceptor).
Each anatomo-histopathological slide will be re-read 3 times:
* Reading 1: first reading by a pathologist in the care setting
* Reading via the standard care procedure (microscope and physical slides)
* Reading 2: Second reading by another pathologist from the same center, as part of the research.
* Reading via the standard procedure of care (microscope and physical slides)
* Reading 3: Third reading by the initial physician, with the algorithmic tool MoSi4BCa after digitization of the slides by a laboratory technician and after a wash-out period of 2 months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Understanding French
* With symptoms of breast cancer that required a biopsy (microbiopsy or macrobiopsy or surgical biopsy) and pathological examination diagnosing breast cancer
* First diagnosis of invasive breast cancercarcinoma
* Affiliated to a social security system
* Agreeing to participate in the study
Exclusion Criteria
* Not affiliated to the social security system
* Minor or under legal protection
* Patient with a history of breast cancer
* Patient previously treated for breast cancer
* Patient who has relapsed from breast cancer treatment
* Non ductal or non lobular invasive breast cancer carcinoma
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP211593
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.